Heterogeneity in primary colorectal cancer and its corresponding metastases: A potential reason of EGFR-targeted therapy failure?

Hepato-Gastroenterology

Volumn 58, Issue 106, 2011, Pages 411-416

  Li, Zhongqi ^a   Jin, Ketao ^a,b   Lan, Huanrong ^b   Teng, Lisong ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Epidermal growth factor receptor; Heterogeneity; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; VASCULOTROPIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; COLORECTAL CANCER; DRUG TARGETING; DRUG TREATMENT FAILURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOSS; GENE MUTATION; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; MONOTHERAPY; ONCOGENE K RAS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW;

COLORECTAL NEOPLASMS; HUMANS; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT FAILURE;

EID: 79958171756     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 22:337-345. (Pubitemid 38944402)
2. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208. (Pubitemid 41079832)
3. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-1634.
4. Bokemeyer C, Bondarenko I, Hartmann JT, et al: KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26: abstr 4000.
5. De Roock W, Piessevaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19:508-515. (Pubitemid 351325672)
6. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26:5705-5712.
7. Loupakis F, Ruzzo A, Cremolini C, et al: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101:715-721.
8. Cappuzzo F, Varella-Garcia M, Finocchiaro G, et al: Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008; 99:83-89. (Pubitemid 351920237)
9. Moroni M, Veronese S, Benvenuti S, et al: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279-286. (Pubitemid 40590264)
10. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67:2643-2648. (Pubitemid 46548951)
11. Lièvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374-379. (Pubitemid 351171687)
12. Rajagopalan H, Bardelli A, Lengauer C, et al: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418:934. (Pubitemid 34976022)
13. De Roock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11:753-762.
14. Di Fiore F, Blanchard F, Charbonnier F, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96:1166-1169. (Pubitemid 46625066)
15. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25:3230-3237. (Pubitemid 47325606)
16. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663-671.
17. Laurent-Puig P, Cayre A, Manceau G, et al: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27:5924-5930.
18. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091-2096.
19. Frattini M, Saletti P, Romagnani E, et al: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97:1139-1145.
20. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765.
21. Loupakis F, Pollina L, Stasi I, et al: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27:2622-2629.
22. Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-3995.
23. Gonçalves A, Esteyries S, Taylor-Smedra B, et al: A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer 2008; 8:169.
24. Lurje G, Nagashima F, Zhang W, et al: Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res 2008; 14:7884-7895.
25. Tejpar S, Peeters M, Humblet Y, et al: Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data). J Clin Oncol 2008 26:abstr 4001.
26. Bibeau F, Lopez-Crapez E, Di Fiore F, et al: Impact of Fc-γ RIIa-Fcγ RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27:1122-1129.
27. Garm Spindler KL, Pallisgaard N, Rasmussen AA, et al: The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009; 20:879-884.
28. Prenen H, De Schutter J, Jacobs B, et al: PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009; 15:3184-3188.
29. Sartore-Bianchi A, Martini M, Molinari F, et al: PIK-3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69:1851-1857.
30. Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563-572.
31. Van Cutsem E, Könne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-1417.
32. Qiu LX, Mao C, Zhang J, et al: Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies. Eur J Cancer 2010 Jun 24. (Epub ahead of print)
33. Ding L, Ellis MJ, Li S, et al: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464:999-1005.
34. Shah SP, Morin RD, Khattra J, et al: Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461:809-813.
35. Bachtiary B, Boutros PC, Pintilie M, et al: Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin Cancer Res 2006; 12:5632-5640.
36. Brulliard M, Lorphelin D, Collignon O, et al: Nonrandom variations in human cancer ESTs indicate that mRNA heterogeneity increases during carcinogenesis. Proc Natl Acad Sci USA 2007; 104:7522-7527.
37. Sjöblom T, Jones S, Wood LD, et al: The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-274. (Pubitemid 44571966)
38. Wood LD, Parsons DW, Jones S, et al: The genomic landscapes of human breast and colorectal cancers. Science 2007; 318:1108-1113. (Pubitemid 350134889)
39. Andersen CL, Wiuf C, Kruhøffer M, et al: Frequent occurrence of uniparental disomy in colorectal cancer. Carcinogenesis 2007; 28:38-48. (Pubitemid 44942625)
40. Losi L, Baisse B, Bouzourene H, Benhattar J: Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 2005; 26:916-922. (Pubitemid 41214320)
41. Lips EH, van Eijk R, de Graaf EJ, et al: Progression and tumor heterogeneity analysis in early rectal cancer. Clin Cancer Res 2008; 14:772-781. (Pubitemid 351231159)
42. Flyger HL, Larsen JK, Nielsen HJ, Christensen IJ: DNA ploidy in colorectal cancer, heterogeneity within and between tumors and relation to survival. Cytometry 1999; 38:293-300. (Pubitemid 30029865)
43. Giaretti W, Rapallo A, Sciutto A, et al: Intratumor heterogeneity of k-ras and p53 mutations among human colorectal adenomas containing early cancer. Anal Cell Pathol 2000; 21:49-57. (Pubitemid 32238922)
44. Planck M, Halvarsson B, Pålsson E, et al: Cytogenetic aberrations and heterogeneity of mutations in repeat-containing genes in a colon carcinoma from a patient with hereditary nonpolyposis colorectal cancer. Cancer Genet Cytogenet 2002; 134:46-54. (Pubitemid 34462109)
45. Lassmann S, Bauer M, Soong R, et al: Quantification of CK20 gene and protein expression in colorectal cancer by RT-PCR and immunohistochemistry reveals inter- and intratumour heterogeneity. J Pathol 2002; 198:198-206. (Pubitemid 35243877)
46. Halvarsson B, Müller W, Planck M, et al: Phenotypic heterogeneity in hereditary non-polyposis colorectal cancer: identical germline mutations associated with vari- able tumour morphology and immunohistochemical expression. J Clin Pathol 2007; 60:781-786. (Pubitemid 47056907)
47. Whitehall VL, Wynter CV, Walsh MD, et al: Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res 2002; 62:6011-6014. (Pubitemid 35244444)
48. Baldus SE, Schaefer KL, Engers R, et al: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16:790-799.
49. Kuwai T, Nakamura T, Kim SJ, et al: Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors. Am J Pathol 2008; 172:358-366. (Pubitemid 351282023)
50. Giaretti W, Monaco R, Pujic N, et al: Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas: association with degree of DNA aneuploidy. Am J Pathol 1996; 149:237-245. (Pubitemid 26230995)
51. Al-Mulla F, Going JJ, Sowden ET, et al: Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol. 1998; 185(2):130-138.
52. Barry WT, Kernagis DN, Dressman HK, et al: Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol 2010; 28:2198-2206.
53. Tortola S, Steinert R, Hantschick M, et al: Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J Clin Oncol 2001; 19:2837-2843. (Pubitemid 32538192)
54. Artale S, Sartore-Bianchi A, Veronese SM, et al: Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26:4217-4219.
55. Molinari F, Martin V, Saletti P, et al: Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 2009; 100:1087-1094.
56. Jones S, Chen WD, Parmigiani G, et al: Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA 2008; 105:4283-4288. (Pubitemid 351754372)
57. Santini D, Loupakis F, Vincenzi B, et al: High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 2008; 13:1270-1275.
58. Weber JC, Meyer N, Pencreach E, et al: Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes. Int J Cancer 2007; 120:524-532. (Pubitemid 44969022)
59. Albanese I, Scibetta AG, Migliavacca M, et al: Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 2004; 325:784-791. (Pubitemid 39487940)
60. Hüsemann Y, Geigl JB, Schubert F, et al: Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13:58-68. (Pubitemid 350309740)
61. Yang Y, Forslund A, Remotti H, et al: P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. Cancer 2001; 91:727-736. (Pubitemid 32173297)
62. Yao J, Goh HS, Smith DR: p53 mutations in primary colorectal adenocarcinomas and liver metastases. Br J Surg 1996; 83:1245-1246. (Pubitemid 26290455)
63. Zhang JS, Caplin S, Bosman FT, Benhattar J: Genetic diversity at the p53 locus between primary human colorectal adenocarcinomas and their lymph-node metastases. Int J Cancer 1997; 70:674-678. (Pubitemid 27158446)
64. Monaco SE, Nikiforova MN, Cieply K, et al: A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol 2010; 41:94-102.